Skip to main content
FBIO
NASDAQ Life Sciences

Fortress CEO/Chairman Rosenwald Buys 136,723 Shares for $252,583

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$1.89
Mkt Cap
$59.031M
52W Low
$1.64
52W High
$4.53
52W Position info
15% above low
Off High info
58% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

FBIO sits 15% above its 52-week low of $1.64.

Summary

Fortress Biotech's CEO and chairman Lindsay Rosenwald bought 136,723 shares in the open market for $252,583 over Nov 17-19, 2026, lifting his direct stake to 4,723,564 shares. The move follows the CFO's $87,814 purchase over the same days and the Nov 13 Q3 report.


Key Events · Ownership and Investor Activity · FBIO

  • CEO/Chairman Open-Market Purchase

    Lindsay A. Rosenwald bought 136,723 shares in three trades from Nov 17-19, 2026, for $252,583.16 total, at weighted-average prices of $1.7973, $1.9029 and $1.8584.

  • Stake Rises to 4.72 Million Shares

    Direct ownership rose to 4,723,564 shares after the purchases, up from 4,651,332 before the first trade.

  • Second Insider Buying This Week

    The purchases follow CFO David Jin's 47,605-share, $87,814 open-market buy over the same Nov 17-19 window, disclosed in a separate Form 4.

  • Timing After Q3 Results

    Buying came after the Nov 13 Q3 filing showing $19.2 million of revenue, $152.2 million of cash and no parent-level debt following repayment of the Oaktree facility.


Analysis · FBIO · Life Sciences

Why it matters: the CEO, president and chairman put $252,583 of his own money into open-market purchases over three sessions, paying $1.80-$1.90 a share. That is real cash, not an option exercise. It also comes days after the Q3 report showed $19.2 million of quarterly revenue, $152.2 million of cash and no parent-level debt following the Oaktree repayment. For a micro-cap, the buying is a meaningful slice of the float, and it pairs with the CFO's separate $87,814 purchase over the same Nov 17-19 window — two senior insiders accumulating at the same time.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, FBIO was trading at $1.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $59M. The 52-week trading range was $1.64 to $4.53. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

FBIO - Latest Insights

FBIO
Nov 13, 2026, 8:16 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $1.95
Real-time Price: $1.89 info
Change: -$0.0638 (-3%) info
Market Cap: $59.031M info
FBIO
Aug 13, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.96
Real-time Price: $1.89 info
Change: -$1.07 (-36%) info
Market Cap: $59.031M info
FBIO
May 14, 2026, 4:31 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $2.34
Real-time Price: $1.89 info
Change: -$0.450 (-19%) info
Market Cap: $59.031M info
FBIO
May 14, 2026, 4:23 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $2.34
Real-time Price: $1.89 info
Change: -$0.450 (-19%) info
Market Cap: $59.031M info
FBIO
May 14, 2026, 4:20 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $2.33
Real-time Price: $1.89 info
Change: -$0.440 (-19%) info
Market Cap: $59.031M info